AstraZeneca plc (LON:AZN) had its price objective upped by equities research analysts at Jefferies Group LLC from GBX 4,350 ($56.18) to GBX 4,800 ($61.99) in a research note issued on Monday. The brokerage currently has a “hold” rating on the biopharmaceutical company’s stock. Jefferies Group LLC’s price target indicates a potential downside of 2.54% from the company’s current price.

A number of other research analysts have also weighed in on AZN. Deutsche Bank AG boosted their target price on AstraZeneca plc from GBX 5,350 ($69.09) to GBX 5,700 ($73.61) and gave the stock a “buy” rating in a report on Monday, May 15th. HSBC Holdings plc reaffirmed a “reduce” rating and issued a GBX 4,200 ($54.24) price objective on shares of AstraZeneca plc in a report on Monday, May 15th. Shore Capital raised AstraZeneca plc to a “hold” rating and set a GBX 4,800 ($61.99) price objective on the stock in a report on Tuesday, May 16th. Berenberg Bank upped their price objective on AstraZeneca plc from GBX 5,670 ($73.23) to GBX 5,850 ($75.55) and gave the company a “buy” rating in a report on Wednesday, May 17th. Finally, Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($50.37) price objective on AstraZeneca plc and gave the company a “sell” rating in a report on Saturday, May 20th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and ten have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of GBX 4,963.82 ($64.11).

Shares of AstraZeneca plc (LON AZN) opened at 4887.50 on Monday. The firm’s market cap is GBX 61.88 billion. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00. The stock has a 50 day moving average of GBX 4,566.85 and a 200 day moving average of GBX 4,882.53.

COPYRIGHT VIOLATION WARNING: This article was first reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at

In other AstraZeneca plc news, insider Nazneen Rahman bought 39 shares of the firm’s stock in a transaction that occurred on Thursday, July 27th. The stock was acquired at an average price of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with's FREE daily email newsletter.